Very positive article on EDAP's future and its advances on #HIFU, written by Seeking Alpha. Summary - Favorable changes in market acceptance and reimbursement for the FocalOne have been obscured by pandemic headwinds. - However, the company continues at breakeven because of strong growth in its distribution business, the result of a fantastic strategic deal with Exact Imaging. - While pandemic headwinds could blow a little longer, sooner or later the lid will be blown off of FocalOne installation growth and as long as the distribution business. - As long as the distribution business keeps on delivering, the wait isn't problematic and the shares are already attractive at $6 and change.

Attachments

  • Original document
  • Permalink

Disclaimer

Edap TMS SA published this content on 07 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2021 14:11:04 UTC.